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Collagen is the major protein of skeletal and connective tissues. Genetically distinct 
types  of collagen,  although  similar  in  macromolecular  structure,  differ  in  primary 
structure  and  contain  diverse  antigenic  determinants  (1).  In addition,  post-transla- 
tional  modifications  result  in  further  differences  in  collagens  of similar  primary 
structure.  These modifications include hydroxylation of proline and lysine,  glycosyl- 
ation of amino acids involved in the glycopeptide bonds, and the subsequent assembly 
of carbohydrate  units  (2).  Glucosylgalactosyl  and  galactosyl  residues  attached  to 
hydroxylysine are the major forms of carbohydrates  in collagen  (3-7).  These carbo- 
hydrate units may be considered a  structural  characteristic  exclusive to the collagen 
family of proteins because hydroxylysine is found almost exclusively in collagen  (8). 
However,  both  a  subcomponent  of the  first  component  of the  complement  system, 
Clq (9), and acetycholine esterase (10, 11) contain collagen-like triple helical structures 
as well as significant quantities  of these carbohydrate moieties.  Basement membrane 
(type  IV)  collagen,  in  addition  to  the  hydroxylysine-linked  carbohydrate,  contains 
asparagine-linked  heteropolysaccharide  in  the  nonhelical  procollagen  extensions; 
however, this carbohydrate-peptide linkage is also found in a  large variety of proteins 
of diverse origin (6). 
We previously demonstrated the ability of type IV collagen, isolated from syngeneic, 
murine Engelbroth-Holm/Swarm sarcoma, to induce a collagen type IV-specific cell- 
mediated  immune  response  in  a  murine  model  (12).  Mice  sensitized  to  type  IV 
collagen  in  adjuvant  developed  significant  delayed-type  hypersensitivity  responses 
(DTH) ~ to type IV collagen;  no response was observed in these mice after challenge 
with  homologous  type  I  collagen.  This  response  was  characterized  by  an  intense 
mononuclear cell infiltrate in the footpad lesions of immune mice after challenge with 
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type IV collagen and  by the ability of type IV collagen immune T  lymphocytes to 
adoptively transfer this DTH  response to normal, syngeneic mice. 
In  the  present  study,  we  demonstrate  DTH  to  homologous  type  I  collagen that 
cross-reacts with  type  IV  collagen.  Mice  receiving a  single  sensitizing injection  of 
native or denatured type I collagen in adjuvant mount a significant DTH  response to 
challenge with native or denatured type I collagen as well as native type IV collagen. 
The cross-reactive cell-mediated immunity  (CMI)  is eliminated by denaturation  of 
the type IV collagen molecule or by the chemical or enzymatic removal of carbohy- 
drate  components.  Treatment  of type  IV  collagen  with  a-glucosidase  appears  to 
localize the cross-reactive antigenic determinant to a  glucose-containing determinant. 
In contrast, antibodies generated to type I  collagen in this model were collagen type 
specific and did not react with other collagenous or noncollagenous connective tissue 
components.  Thus,  these studies demonstrate  that  collagen-immune T  lymphocytes 
are capable of recognizing antigenic determinants shared by genetically distinct types 
of collagen. 
Materials  and  Methods 
Animals.  C57BL/6 female mice (Laboratory Animal Medicine, Medical University of South 
Carolina) were used at 8-10 wk of age. 
Preparations and  Characterization of Collagenous Proteins.  Type  I  collagen was  isolated from 
murine tail tendon as described previously (12).  Denatured type I collagen was prepared by 
heating a solution of collagen (0.1 mg/ml) in 0.1  M  acetic acid for 30 min at 50°C. 
The  Engelbroth-Holm/Swarm  (EHS)  sarcoma  was  the  source  of type  IV  collagen  as 
previously detailed (12,  13). Briefly, homogenized tumor tissue was extracted with neutral salt 
buffers to remove soluble extracellular proteins and noncollagenous glycoproteins. The residue 
was solubilized in 0.5 M  acetic acid and the insoluble collagenous material treated with pepsin 
(50 mg/g) for 24 h at 4°C. Solubilized protein was precipitated with 10% NaC1, dissolved in 2 
M  urea (0.05  M  Tris-HCl, pH 8.6), and separated by DEAE-cellulose chromatography. The 
collagen  that  appeared  with  the  buffer  front  was  dialyzed against  0.05%  acetic  acid  and 
lyophilized. 
Before  denaturation  of type  IV  collagen,  a  solution  of the  collagen  in  0.1  M  sodium 
phosphate, pH 8.0,  containing 0.4 M  NaCI, was reduced by the addition of 0.02  M  dithioe- 
rythritol and  alkylated with 0.08  M  sodium  iodoacetate to block free sulfb.ydryl groups as 
described by Timpl et al. (14).  These reagents were removed by dialysis against 0.1  M  acetic 
acid.  Denatured  type IV collagen was  prepared by  heating  a  solution of the  reduced and 
alkylated collagen (0.1 mg/ml) in 0.1 M  acetic acid for 30 rain at 50°C. 
Collagen types I and IV were assayed for purity by amino acid analysis, sodium dodecyl- 
sulfate  polyacrylamide gel  electrophoresis  (SDS-PAGE), and  susceptibility to  protease-free 
bacterial collagenase (15). No evidence of other collagenous proteins or noncollagenous impur- 
ities was observed in the collagen preparations, as previously described (12). 
Chemical and Enzymatic Removal of Carbohydrate Moieties from  Collagen.  Periodate oxidation of 
types I  and  IV collagen was carried out in 0.05  M  acetate buffer (pH 4.5), as described by 
Spiro (16). To each of the samples (2.5 mg/ml), an equal volume of 0.04 M  NaIO4 in 0.05 M 
acetate buffer (pH 4.5) was added, and the samples were kept in the dark for 90 rain at 4°C. 
The samples were subsequently dialyzed against phosphate-buffered saline (PBS). 
Types IV and I collagen (2 mg/ml) were dialyzed against PBS and then incubated with an 
equal volume of mixed glycosidase (0.05 mg/ml) from T. Cornutus (Miles Laboratories, Elkhart, 
IN) in the presence of 2 mM MgCIz (17).  The mixed glycosidase was previously assayed for 
proteolytic and collagenolytic activity by the release of radioactive label ([3H]tryptophan and 
[3H]proline) from chick protein, as previously described (12,  15). No activity was demonstrated 
by the mixed glycosidase on these protein substrates. 
Treatment  of type IV collagen with  a-glucosidase or /~-galactosidase was  modified from 
methods described by Spiro (18). a-Glucosidase (Brewer's yeast; Sigma Chemical Co., St. Louis, 1044  CROSS-REACTIVITY BETWEEN TYPES I AND IV COLLAGEN 
MO) at a concentration of 10 U/ml was added to a solution of type IV collagen (1 mg/ml) in 
0.2 M sodium acetate buffer (pH 5.0) and incubated at 37°C for 3 h. fl-Galactosidase (25 U/ 
ml; Escherichia coli, Sigma  Chemical Co.)  was  incubated with  type  IV  collagen in 0.5  M 
potassium phosphate (pH 7.0) in the presence of 0.01 M  MgSO4 for 3 h at 37°C. Sequential 
treatments of type  IV  collagen with  ~x-glucosidase and fl-galactosidase were  performed  as 
described above; after a-glucosidase treatment, type IV collagen samples were dialyzed against 
0.5  M  potassium  phosphate  (pH  7.0) before  the  addition of fl-galactosidase.  All collagen 
samples  were  dialyzed against  PBS.  Control  samples  and  the  glycosidase-treated type  IV 
collagen preparations were prepared by the addition of appropriate concentrations  of the mixed 
glycosidase, ~-glucosidase, or fl-galactosidase immediately before dialysis. 
Collagen samples treated with periodate or glycosidases were assayed for total hexose by the 
anthrone reaction (19). All samples displayed a significant reduction in the amount of hexose 
present when compared with type IV collagen controls. 
Delayed-type Hypersensitivity.  5 #g of antigen in 0.1 ml 0.1 M acetic acid was emulsified with 
an equal  volume of complete Freund's adjuvant (CFA;  Gibco Laboratories, Grand Island 
Biological  Co., Grand Island, NY) and injected subcutaneously in the abdomen. Control mice 
were untreated. DTH was measured by footpad swelling in response to antigenic challenge, as 
described previously (12). On days 3, 6,  10, and  13, mice were injected intradermally in the 
plantar surface of the hindfoot with 5/.tg antigen in a volume of 0.03 ml. Footpad thickness was 
determined 4 and 24 h post-challenge with a  micrometer and compared with measurements 
observed before antigen injection. The data are expressed  as  the  mean percentage footpad 
swelling +  SE: percent footpad swelling =  ([mm after challenge -  mm before challenge]/[mm 
before challenge]) ×  100. 
Passive Transfer.  Spleens removed from collagen-sensitized mice  7 d  after  immunization 
were  passed  through  60-mesh stainless steel  screens  into RPMI  1640 (Gibco Laboratories, 
Grand Island Biological  Co.)  with  2.5% fetal  calf serum  to  obtain single cell  suspensions. 
Erythrocytes were  lysed  by hypotonic shock,  and ceils were washed three times with RPMI. 
The sensitized spleen cells were left untreated or were incubated with monoclonal murine anti- 
Thy-1.2 antibody (anti-Thy-1.2; New England Nuclear, Boston, MA) plus guinea pig comple- 
ment  (C;  M.  A.  Bioproducts,  Walkersville, MD),  as  previously described  (12). 25  million 
untreated or T  cell-depleted spleen cells were  injected intraperitoneally in 0.5  ml PBS  into 
normal mice. 2 d after cell transfer, recipient mice were challenged in the footpad with 5/xg 
antigen, and footpad swelling was assayed 24 h later. 
Preparation of Antisera.  Rabbit gamma globulin fractions against types I  and IV collagen 
were prepared as described previously (20). Lyophilized antibodies were used as a stock solution 
of 1 mg/ml. 
Mice were immunized at weekly intervals by subcutaneous injections of 50 p,g native types 
I or IV collagen dissolved  in 0.1 ml 0.1 M acetic acid and emulsified with an equal volume of 
incomplete Freund's adjuvant (IFA, Gibco Laboratories, Grand Island Biological Co.). Control 
mice were  injected with 0.1  ml 0.1  M  acetic acid emulsified with an equal volume of IFA. 
Immune and normal mice were bled from the ophthalmic venous plexus on day 42. Sera from 
each group (at least six mice per group) were pooled at stored at -70°C. 
Enzyme-linked Immunosorbent Assay (ELISA).  Antibodies to  types  I  and  IV  collagen were 
detected using the ELISA, as described previously (20-22). Serial dilutions of rabbit antibodies 
and immune mouse sera in PBS  (pH  7.8) containing 0.05% Tween 20 and  1% bovine serum 
albumin (PBS-Tween-BSA) applied to polystyrene microtiter wells  (Flow Laboratories, Mc- 
Lean, VA), previously coated with 0.25/~g type IV collagen or  1.25/xg type I collagen, were 
incubated for  45  rain at  room  temperature.  After extensive washing,  100 /~1  of peroxidase- 
conjugated goat  anti-rabbit immunoglobulin (IgG,  M,  A)  antibodies (1:500;  N.  L.  Cappel 
Laboratories Inc., Cochranville, PA) or peroxidase-conjugated goat anti-mouse Ig (IgG, M, A) 
antibodies (1:250; N. L. Cappel Laboratories Inc.) in PBS-Tween-BSA were added. The plates 
were  incubated for  an  additional 45  min and  then  washed.  100  /.d  0.03% 2,2'-azino-di(3- 
ethylbenzthiazoline-6-sulfonate)  (Sigma Chemical Co.) was added to each well in 0.1 M citrate 
buffer (pH 4.0) with 0.05% H202, and, after incubation for 1 h, absorbance was read at 414 nm 
on a Titertek Multiskan (Flow  Laboratories Inc., Rockville, MD). Assays were performed in 
duplicate and results expressed  as mean absorbance values. ANNE  M.  MACKEL,  FRANK  DeLUSTRO,  AND  E.  CARWILE  LeROY  1045 
Absorption Assays.  Repeated absorptions of normal and immune mouse sera (1:20 dilution) 
were performed to remove collagen-specific antibody activity, as previously described (20). 
Results 
The  ability  of C57BL/6  mice  to  mount  a  DTH  response  to  homologous  type  I 
collagen is shown in Fig. I. Mice sensitized with native type I collagen and challenged 
with  native  or  denatured  type  I  collagen  or  native  type  IV  collagen  displayed 
significant footpad swelling peaking 7 d postsensitization  (Fig.  1 A). Mice immunized 
with denatured  type I collagen  in CFA displayed significant  footpad swelling 24 h 
after challenge  with native  or denatured  type  I collagen  as  well as  native  type  IV 
collagen  (Fig.  1 B).  No  significant  reactivity  was  observed  in  either  group  when 
challenged  with  denatured  type  IV  collagen.  Normal  control  mice  displayed  no 
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FIG.  1.  DTH  response of mice sensitized with 5/tg (A)  native type I collagen, or (B)  denatured 
type l  collagen, and  (C)  normal mice challenged on days 3,  6,  10, and  13 postsensitization with 
native type I collagen (~), denatured type I collagen ~), native type IV collagen (Ira), or denatured 
type IV collagen (]~. The percent footpad swelling was assayed 24 h post-challenge, and the results 
are expressed as mean percentage footpad swelling _  SE. The number of mice assayed is indicated 
above each bar. 1046  CROSS-REACTIVITY BETWEEN TYPES  I  AND  IV COLLAGEN 
or  IV  collagen  (Fig.  1 C).  No  significant swelling was  observed  4  h  after  challenge 
with  types  I  or  IV  collagen  (data  not  shown),  indicating the  response  was  not  the 
result  of an  immediate  hypersensitivity  response  or  an  antibody-mediated  Arthus 
reaction. These data  indicate that  a  CMI  response to type I  collagen may recognize 
similar antigenic determinants on type IV collagen; the cross-reactive DTH  response 
is specific for the native form of type IV collagen. 
Although  no  collagenous  or  noncollagenous contaminants  were  observed  in  our 
collagen preparations  by biochemical  and  immunological analyses  (12,  20-22),  the 
possibility that  a  noncollagenous protein  contaminant  was  contributing to  the  ob- 
served cross-reactive DTH  response between types I and IV collagen was investigated 
by challenging type I  collagen-sensitized mice with collagenase-treated  antigens. As 
shown  in Table  I,  mice sensitized  with  type  I  collagen  and  challenged  with  either 
collagenase-treated  type  I  or  type  IV  collagen  failed  to  show  significant  footpad 
swelling on day 7. Challenge of these same mice with untreated types I or IV collagen, 
immediately after assay of the footpad swelling on day 7, resulted in significant DTH 
responses 24 h  later  (day 8)  in both groups of mice, indicating that  mice immune  to 
type I  collagen respond to collagenous antigenic determinants. 
The  ability  of  type  I  and  type  IV  collagen  immune  spleen  cells  to  adoptivety 
TABLE  I 
Collagenase Treatment of Antigen Preparations Used for DTH Challenge* 
Sensitization  Challenge 
Footpad swelling 
With collagenase  Without collagenase 
mean % +_ SE 
I  I  0.4+0.1  11.0+-  1.0 
I  IV  0.4 ---+ 0.1  8.3  --- 0.8 
* Three mice per group were sensitized with 5 ~g type I collagen in CFA and 
challenged  on day 6 with 5 p.g collagenase-treated  collagen  preparations. 
Footpad swelling was determined on day 7 (24 h post-challenge),  and the 
mice  were  immediately challenged  with  untreated collagen  preparations. 
Footpad swelling was again determined after 24 h (day 8). 
TABLE  II 
Adoptive  Transfer of DTH to Type IV Collagen Using Untreated and T 
Cell-depleted Sensitized Spleen Cells 
Sensitiza-  Cell treatment  Chal-  Number  Footpad 
tion  lenge  of mice  swelling 
mean % +_ SE 
IV  None  IV  4  9.2 + 0.8 
IV  Anti-Thy-l.2 + C  IV  4  1.1 +_ 0.5 
I  None  IV  5  7.4 _  0.8 
I  Anti-Thy-l.2 + C  IV  5  2.3 + 0.4 
[  None  I  4  7.2 _+ 0.2 
I  Anti-Thy-1.2 + C  I  4  1.8 + 0.6 
* Donor mice were immunized with 5 #g antigen in CFA. At day 7, 25 X 106 
treated  or  untreated sensitized  spleen  cells  were  transferred  per  normal 
recipient. 
Recipient mice were challenged with 5/~g types IV or I collagen 48 h after 
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transfer DTH  responsiveness to normal syngenic mice is shown  in Table II. Spleen 
cells were obtained from type I or type IV collagen sensitized mice on day 7, the peak 
of the  DTH  response  (Fig.  1).  Mice  receiving  an  injection  of untreated  type  IV 
collagen-sensitized  spleen  cells  displayed  significant  footpad  swelling  24  h  after 
challenge with type IV collagen. This response was eliminated by T  cell depletion of 
the immune spleen cells with a  monoclonal murine anti-Thy-1.2 antibody plus C, as 
previously described  (11).  Mice receiving type  I  collagen-sensitized spleen cells ex- 
hibited  significant  DTH  responsiveness  after  challenge  with  both  types  I  and  IV 
collagen. Type I collagen-sensitized spleen cells treated with the anti-Thy-1.2 antibody 
plus C  were unable to adoptively transfer a  DTH  response. These data indicate that 
sensitized T  lymphocytes are responsible for mediating the observed DTH  responses 
to types I and IV collagen. 
Immunological studies involving an oligosaccharide are difficult to perform using 
the classical procedures developed for pure  carbohydrates,  such  as acid hydrolysis, 
because denaturation  of the molecule results.  However,  periodate oxidation can  be 
performed on the native protein under relatively mild conditions of temperature and 
pH,  and  has  been  shown  to  degrade  the  carbohydrate  units  of glyeopeptides (16). 
Mice sensitized with type I collagen displayed no significant footpad swelling on day 
7,  when  challenged with  periodate-treated type IV collagen, as shown  in Table III. 
Periodate  treatment  of type  IV  collagen  did  not  significantly alter  the  previously 
described  (12)  DTH  response  in  type  IV  collagen-sensitized  mice.  Normal  mice 
exhibited no significant reactivity at any time when challenged with periodate-treated 
TABLE  III 
Periodate Treatment of Antigen  Preparations  Used for DTH Challenge 
Sensitization*  Challenge:~  Number of  Footpad 
mice  swelling 
mean % ± SE 
None  Periodate-treated IV  4  1.0 ± 0.5 
I  Periodate-treated IV  8  2.5 ± 0.3 
IV  Periodate-treated IV  4  9.4 ±  1.1 
* Mice were sensitized on day 0 with  5 #g types I or IV collagen in CFA; 
normal controls were untreated. 
:]: Mice were challenged on day 6 with 5/zg antigen, and the footpad swelling 
was assayed 24 h later (day 7), as indicated in Materials and Methods. 
TABLE IV 
Glycosidase Treatment  of Collagen Preparations 
Sensitization  Challenge  Number of  Footpad 
mice  swelling* 
mean % ± SE 
None  Glycosidase-treated IV  6  1.5 ± 0.4 
I  Glycosidase-treated IV  11  1.1 ± 0.3 
Glycosidase-treated I  IV  8  2.9 ± 0.7 
I  Glycosidase-treated IV (control)  4  9.2 ± 0.5 
IV  Glycosidase-treated IV  4  7.6 ± 0.5 
Glycosidase-treated IV  IV  4  7.4 ±  1.1 
* Mice were challenged on day 6 post-sensitization, and the footpad swelling was assayed 24 
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TABLE  V 
Reactivity of e~-glucosidase and ~-galactosidase Treated Type IV Collagen in DTH Response 
Sensitiza-  Number of 
tion  Challenge  mice  Footpad swelling* 
mean % + SE 
None  a-glucosidase-treated  IV  5  2.4 -t- 0.7 
None  /~-galactosidase-treated  IV  5  1.5 --- 0.6 
None  a-glucosidase//~-galactosidase-treated  IV  6  1.2 + 0.4 
I  o~-glucosidase//~-galactosidase-treated  IV  11  3.1 + 0.8 
I  a-glucosidase-treated  IV  11  1.9 + 0.3 
I  fl-galaetosidase-treated  IV  10  8.5 +  1.1 
I  a-glucosidase/fl-galactosidase-treated  IV (control)  4  8.5 + 0.6 
IV  a-glucosidase/,8-galaetosidase-treated  IV  4  8.0 +  1.0 
* Mice were challenged on day 6  post-sensitization, and the footpad swelling was assayed 24 h  later, as 
indicated in Materials and Methods. 
type IV collagen. These data indicate that the cross-reactive determinants on types I 
and IV collagen are periodate sensitive and probably related to carbohydrates. The 
carbohydrate moieties on  type IV collagen,  however, do not  appear to be the sole 
antigenic determinants responsible for DTH in type IV collagen-sensitized mice. 
Because of the heterogenous effects of periodate on glycoproteins (23), types I and 
IV collagen  were treated with  a  mixture of glycosidases before use in  DTH  assays. 
Mice  sensitized  with  type I  collagen  showed  no  significant  footpad  swelling when 
challenged  with  glycosidase-treated  type  IV  collagen;  in  addition,  no  significant 
reactivity was observed in groups of mice immunized with glycosidase-treated type I 
collagen and challenged with untreated  type IV collagen  (Table IV). However, type 
I  collagen-sensitized  mice did display significant  reactivity when  challenged with  a 
glycosidase-treated type IV control  (enzyme added  before dialysis).  Mice sensitized 
with untreated  type IV collagen or glycosidase-treated type IV collagen did exhibit 
significant  footpad  swelling  responses  when  challenged  with  either  treated  or  un- 
treated  type IV collagens.  Normal controls  showed  no significant  footpad swelling 
when challenged with glycosidase-treated type IV collagen preparations. These data 
give more definitive proof that carbohydrate moieties are involved in the cross-reactive 
DTH response between types I and IV collagen; however, carbohydrate molecules do 
not  appear  to  be  the  major  antigenic  determinants  responsible  for  mediating  the 
DTH reactivity in type IV collagen-immune mice. 
Because the major carbohydrate component found on types I and IV collagen is a 
dissaccharide  unit  containing  glucose  and  galactose  (3,  6),  type  IV  collagen  was 
treated with specific glycosidases (~-glucosidase, fl-galactosidase) and assayed for its 
ability to elicit a DTH response in mice sensitized to types I or IV collagen (Table V). 
Mice sensitized with type I collagen in adjuvant and challenged with type IV collagen 
treated with c~-glucosidase alone or a sequentially treated c~-glucosidase//~Lgalactosid- 
ase preparation displayed no significant footpad swelling response; however, challenge 
with  fl-galactosidase-treated  type  IV  collagen  or  an  a-glucosidase//~-galactosidase 
type IV collagen control (enzymes added before dialysis) did not alter the previously 
observed DTH responses (Table V). Furthermore, the ~-glucosidase//~-galactosidase- 
treated  type  IV  collagen  preparation  was  capable  of  eliciting  significant  DTH 
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FIQ. 2.  Analyses of immune and normal mouse sera on (A) type IV and (B) type I collagens using 
the  ELISA.  Serial  dilutions  of mouse anti-type  IV collagen  sera  (O---'-O),  mouse anti-type  I 
collagen  sera  (m),  adjuvant  control  sera  (A),  and  normal mouse sera  (OH--O) were assayed on 
microtiter wells coated  with  (A)  0.25  /zg type  IV collagen  and  (B)  1.25 ~g type I  collagen. The 
results are expressed as the absorbance value at 414 nm. 
type  IV  collagen  treated  with  either  a-glucosidase  alone  or  a  combination  of a- 
glucosidase and fl-galactosidase displayed no significant footpad swelling on day 7. 
These data indicate that carbohydrate-containing antigenic determinants, specifically 
those containing glucose, are responsible for cross-reactivity to type IV collagen in 
type I collagen-sensitized mice. 
The ability of  C57BL/6 mice to elicit an antibody response to homologous collagens 
was  examined using ELISA.  No  antibody was  detected in  sera of mice displaying 
DTH as a  result of a  single sensitizing injection of types I  or IV collagen (data not 
shown); however, repeated injections of 50/xg types IV or I  collagen in IFA elicited 
significant  antibody  responses.  The  anti-type  IV  collagen-immune  sera  displayed 
significant antibody activity (tiler >80) when assayed on wells coated with type IV 
collagen (Fig. 2 A). No significant activity above the level of normal mouse sera was 
exhibited by the type I collagen-immune sera or adjuvant control sera when assayed 
on type IV collagen. Significant antibody activity to type I  collagen was exhibited, 1050  CROSS-REACTIVITY  BETWEEN  TYPES  I  AND  IV  COLLAGEN 
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Fro.  3.  Repeated  absorptions of anti-type  IV collagen  sera  (H),  anti-type  I  collagen  sera 
(R), adjuvant control sera (A), and the normal mouse sera (0----0)  on (A) type IV and  (B) type I 
collagen-coated  wells were  performed  to  remove all  collagen  type-specific  activity.  All  sera were 
assayed at  a  1:20 dilution  on wells coated  with  (A) 0.25 #g type IV collagen or (B)  1.25/~g type I 
collagen. The results are expressed as indicated  in Fig. 2. 
however, by both type I and type IV collagen-immune sera as well as adjuvant control 
sera as shown in Fig. 2 B. The high antibody activity of the IFA control sera indicate 
sensitization to type I collagen as a  result of immunization in adjuvant.  The intense 
inflammatory reaction observed in the skin after subcutaneous injection of adjuvant 
may lead to sensitization to type I collagen with antibody induced to this connective 
tissue protein. 
Sera of mice immune to collagen were assayed for antigen specificity by absorption 
on types I or IV collagen-coated wells. Repeated absorptions of these sera on types IV 
and I collagen were performed to determine whether all collagen type-specific activity 
could be removed. As shown in Fig. 3 A, the reactivity of the type IV collagen-immune 
sera to type IV collagen was eliminated by sequential absorptions on type IV collagen; 
no significant reduction in reactivity to type I collagen was observed by the immune 
sera after absorption on type IV collagen (absorbance values, >0.400). ELISA activity 
of the anti-type I collagen, anti-type IV collagen, and adjuvant control sera with type 
I collagen were reduced to the level of the normal mouse sera by sequential absorptions 
on type I collagen (Fig. 3 B); the reactivity of the type IV collagen-immune sera with 
type IV collagen  was  not  significantly  affected  by repeated  absorptions  on  type  I 
collagen (absorbance values, >0.300). These data indicate that antibodies to types IV 
and I collagen in the sera of collagen-immune mice are antigen specific and do not 
recognize cross-reactive determinants. 
Discussion 
After Watson et al.  (24)  demonstrated  collagen to be immunogenic, studies were 
initiated  to  investigate  the  immunological  characteristics  of the  different  collagen 
types, the relation of collagen structure  to antigenicity,  and  the role of collagens as 
potential  autoantigens.  Cell-mediated and/or  humoral  immunity to interstitial  col- 
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demonstrated in human disease as well as in experimental animal models (1, 21, 25). 
Type I collagen has been implicated as an autoantigen in both rheumatic (20, 26-31) 
and nonrheumatic diseases  (32-35). Humoral immunity and CMI to types I  and II 
collagen  have  been  suspected  to  contribute  to  the  tissue  destruction  observed  in 
rheumatoid  arthritis  (26-30,  36).  Autoantibodies  to  type  IV  collagen  have  been 
reported in patients with basement membrane-associated diseases, including sclero- 
derma (20), Goodpasture's syndrome (37), and epidermolysis bullosa simplex (38). 
Antibodies  to collagen generated in  experimental animal  models and  in  human 
disease appear to recognize collagen type-specific antigenic determinants, as demon- 
strated by competitive inhibition  assays.  Although  collagenous proteins have been 
observed to elicit CMI, few studies have attempted to discern the antigen specificity 
of these  responses,  primarily because of the  experimental limitations  that  exist  in 
measuring  antigen  recognition  by  cells  (1).  Antigen-specific  CMI  to  interstitial 
collagens (types I, II, and III) has been demonstrated in experimental systems (39); 
however, recent studies suggest that CMI to collagen may also result in the induction 
of cross-reactive cellular responses with other collagenous and collagen-like proteins. 
Champion and Poole (40) recently reported that rabbits immunized with homologous- 
type III collagen mount a CMI response to the immunizing peptides that also cross- 
reacts with  types I  and  II collagen.  Furthermore, Menzel et al.  (41)  demonstrated 
cross-reactivity between  human  type I  collagen  and  Clq  (containing  collagen-like 
domains)  in  guinea pigs  at  the  level of delayed-type hypersensitivity. In  addition, 
cellular and humoral cross-reactivity have been shown between rat tail tendon type 
I collagen and the triple helical structure of the electric eel acetylcholinesterase (42), 
a  structure that  appears  to resemble type IV collagen with  respect  to amino  acid 
composition and presence of disulfide bonds (10). 
In the present study, we demonstrate DTH in type I collagen-sensitized mice that 
cross-reacts with  type IV  collagen.  Mice  sensitized  to  native  or  denatured  type I 
collagen  in  CFA  developed  significant  footpad  swelling  responses,  peaking  7  d 
postsensitization, 24 h  after challenge with native or denatured type I  collagen, or 
native type IV collagen;  no response was  observed after challenge with  denatured 
type IV collagen or collagenase-treated collagen preparations.  Our studies are con- 
sistent with previous observations by Adelmann (43) that indicated that sensitization 
with native or denatured type I collagen results in positive DTH after challenge with 
native or denatured antigen. The absence of a cross-reactive DTH response between 
type  I  collagen  and  denatured  type  IV  did  not  appear  to  be  a  result  of protein 
modification after reduction and alkylation of type IV collagen, a procedure used to 
prevent the a  chains from reannealing after heat denaturation, as challenge of type 
I collagen-sensitized mice with reduced and alkylated heat-denatured type I collagen 
did not significantly alter the DTH responses observed in Fig.  1 (data not shown). 
Thus,  these  observations  suggest  that  the  cross-reactivity between  types  I  and  IV 
collagen at  the  level of DTH  involves multiple polypeptide chains of the type IV 
collagen molecule. Although  significant  antibody reactivity to type I  collagen was 
observed in mice receiving repeated immunizations of either type I or type IV collagen 
in IFA, these anti-type I collagen antibodies appeared to be a result of immunization 
in  adjuvant,  as  adjuvant  control  sera  displayed  significant  activity against  type I 
collagen. Absorption experiments performed to determine the collagen type-specificity 
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specific and that the antigenic determinants of these two collagens are distinct in this 
system. 
In an effort to further investigate the nature of the cross-reactive antigenic deter- 
minant (s) present on types I and IV collagen observed at the level of DTH, a common 
structural  component  shared  by  each  collagen  species  was  sought.  Carbohydrate 
components  are  known  to occur in  all  collagens  as  a  result  of a  post-translational 
modifications.  The major carbohydrate components of the interstitial  collagens  are 
glucose  and  galactose.  Structural  investigations  (18,  44,  45)  indicate  that  these 
carbohydrates  are  glycosidically  linked  to  hydroxylysine  in  the  form  of either  a 
glucosylgalactosyl disaccharide (2-O-o~-D-glucopyranosyl-O-~-D-galactopyranosyl-hy- 
droxylysine) or a galactosyl monosaccharide (O-/~-D-galactopyranosyl-hydroxylysine). 
Studies  conducted  by Spiro  et  al.  (18)  suggest  that  basement  membranes contain 
carbohydrate moieties similar to those found in the interstitial collagens. Evidence for 
a potential antigenic role of collagen carbohydrate moieties was provided by Mahieu 
et al. (46) in patients with Goodpasture's syndrome. These investigators demonstrated 
that  the  hydroxylysine-linked  disaccharide  of the  glomerular basement  membrane 
could  specifically react  with  anti-glomerular basement  membrane  antibodies  from 
these patients.  These antibodies primarily reacted with the antigenic site formed by 
the ¢/-D-galactosyl-hydroxylysine unit. Furthermore, this disaccharide-containing gly- 
copeptide  was  able  to  elicit  an  in  vitro  ceLl-mediated  immune  response  in  these 
patients,  as measured by the leukocyte migration inhibition  assay. Recent carbohy- 
drate analyses (13,  47,  48)  of basement membrane collagen  (type IV) derived from 
several tissues revealed a high concentration of glucosyl and galactosyl groups bound 
to hydroxylysine. The 7-S region of the type IV collagen, a  major structural  consti- 
tutent  of type IV collagen, has been shown  by Ristelli  et  al.  (47)  to contain  ~22% 
carbohydrate, mainly as glucosylgalactosyl-hydroxylysine. 
To evaluate the role of carbohydrate moieties in the cross-reactive DTH response 
observed  between  types  I  and  IV  collagen,  the  carbohydrate  components  were 
chemically or enzymatically removed from the collagens before immunological anal- 
yses.  Mice sensitized  to  type I  collagen  in  adjuvant  were unable  to mount  a  DTH 
response to type IV collagen treated with periodate, a  mixture of glycosidases, or c~- 
glucosidase. In addition, mice sensitized to glycosidase-treated type I collagen did not 
display a  footpad swelling response after challenge with untreated type IV collagen. 
Although/~-galactosidase treatment of type IV collagen did not significantly alter the 
DTH response in type I collagen-immune mice, galactose cannot be ruled out as being 
a  component of the antigenic  determinant  because previous studies  by Spiro et  al. 
(18) indicated that galactose can only be removed enzymatically from the disaccharide 
unit  when  the  glucose  is  eliminated  initially,  Thus,  these  studies  indicate  that  a 
glucose-containing antigenic  determinant  found on both types I  and  IV collagen  is 
responsible for the cross-reactive DTH response between these two species of collagen. 
In light of the previously demonstrated collagen-specific CMI response to type IV 
collagen in mice sensitized to homologous type IV collagen (12), the "one-way" cross- 
reactive DTH response between types I and IV collagen is unexplained. Because type 
IV collagen  is  heterogenous  and  contains  diverse  structural  regions,  immunization 
with  type  IV  collagen  may  result  in  induction  of a  CMI  response  preferentially 
directed against non-carbohydrate-containing antigenic determinants. Carbohydrates 
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IV collagen because glycosidase-treated type IV collagen, when used to sensitize or 
challenge, retains its ability to induce a  footpad swelling response. In addition, the 
cross-reactive DTH response does not appear to be the result of lectin-like interaction 
of T  lymphocytes with the collagen carbohydrates. If such a  reaction were relevant, 
a  positive footpad swelling response would  have been observed in  normal  mice or 
glycosidase-treated  type  I  collagen-sensitized  mice  when  challenged  with  type  IV 
collagen (Fig. 1, Tables IV and V). 
Although previous investigations have demonstrated CMI to type I  collagen in a 
number of pathological processes, little is known of the role of cellular immunity to 
type IV collagen in disease. Tissues containing a high concentration of types I and IV 
collagen, such as the lung, are frequent sites of pathological fibrosis. We previously 
demonstrated (20)  antibodies to types I and IV collagen in the sera of patients with 
scleroderma  that  correlated  directly  with  the  extent  of interstitial  lung  disease. 
Furthermore, Kravis et al. (35) reported that fibrotic lung disease was associated with 
sensitization of CMI to type I  collagen, as evidenced by the production of collagen- 
induced macrophage inhibition factor. Our observations suggest that the induction of 
CMI  to  type I  collagen  might  result  in  the  recognition of antigenic  determinants 
shared by type IV collagen. Such a concomitant immune response to these collagenous 
proteins could potentially result in the perpetuation of disease processes, resulting in 
a  chronic  inflammatory response.  Studies  are  currently underway  to examine  the 
possible immunopathological sequelae that might result after the induction of a cross- 
reactive CMI response to types I and IV collagen in this animal model. These studies 
might  lead  to  a  better  understanding  of  the  role  of anti-collagen  CMI  in  the 
pathogenesis of human connective tissue diseases. 
Summary 
In  the  present  study,  we  demonstrate  delayed-type  hypersensitivity  (DTH)  to 
homologous type I collagen that cross-reacts with type IV collagen. Mice immunized 
with native or denatured type I collagens and challenged with these same antigens or 
native type IV collagen  develop a  peak  DTH  response on  day  7.  Challenge with 
denatured type IV collagen or collagenase-treated type IV collagen failed to elicit 
DTH  in  type  I  collagen-sensitized  mice.  Type  I  collagen-sensitized  spleen  cells 
adoptively transferred DTH to types IV and I collagen to normal recipients; T  cell- 
depleted spleen cells failed to transfer immunity. Periodate-treated type IV collagen 
did  not  elicit DTH in  mice sensitized to type I  collagen;  however, mice sensitized 
with type IV collagen displayed significant DTH when challenged with periodate- 
treated type IV collagen. Furthermore, treatment of type IV collagen with a  mixed 
glycosidase or a-glucosidase before challenge eliminated the DTH response in type I 
collagen-sensitized mice;/~-galactosidase treatment of type IV collagen had no effect 
on this response. Mice sensitized with type IV collagen, however, displayed significant 
DTH when challenged with these glycosidase-treated antigens. Antibodies produced 
to types I and IV collagen by repeated immunizations were specific for the sensitizing 
antigen and did not react with other connective tissue antigens. These studies indicate 
that a CMI response to type I collagen recognizes similar antigenic determinants on 
the type IV collagen molecule. These cross-reacting determinants are dependent on 
conformation and contain carbohydrates, particularly glucose residues. 1054  CROSS-REACTIVITY BETWEEN TYPES I AND IV COLLAGEN 
We  thank  Dr.  G.  R.  Vasta  for  helpful suggestions on  carbohydrate  treatments and Judy 
Anderson for secretarial assistance. 
Received for publication  25June  1982. 
References 
1.  Timpl, R.  1976. Immunological studies on collagen. In  Biochemistry of Collagen. G. N. 
Ramachandran and A. H. Reddi, editors. Plenum Publishing Corp., New York.  319-375. 
2.  Prockop, D. G., R. A. Berg,  K. I. Kivirikko, and J. Uitto.  1976. Intracellular steps  in the 
biosynthesis of collagen. In  Biochemistry of Collagen. G.  N.  Ramachandran and A.  H. 
Reddi, editors.  Plenum Publishing Corp. New York.  163-273. 
3.  Spiro, R. G.  1969. Characterization and quantitative determination of the hydroxylysine- 
linked carbohydrate units of several collagens.J. Biol.  Chem. 244:602. 
4.  Cunningham, L. W., and J.  D.  Ford.  1968. A comparison of glycopeptides derived from 
soluble and insoluble collagens.J. Biol.  Chem. 243:2390. 
5.  Seyer, J. M., and A. H. Kang. 1977. Covalent structure of collagen: amino acid sequence 
of cyanogen bromide peptides from the amino-terminal segment of type III collagen of 
human liver. Biochemistry.  16:1158. 
6.  Kefalides, N. A. 1973. Structure and biosynthesis of basement membranes. Int. Rev.  Connect. 
Tissue Res.  6:63. 
7.  Hong, B. S., P.  F.  Davison, and D. J. Cannon. 1979. Isolation and characterization of a 
distinct  type  of collagen  from  bovine fetal  membranes and  other  tissues.  Biochemistry. 
18:4278. 
8.  Spiro, R. G.  1972. Basement membranes and collagens. In Glycoproteins. A. Gottschalk, 
editor. Elsevier Publishing Co., Amsterdam, Netherlands. 964-999. 
9.  Reid, K. B. M.  1979. Complete amino acid sequences of the three collagen-like regions 
present in subcomponent CIq of the first  component of human complement. Biochem. J. 
179:367. 
10.  Anglister, L., and I. Silman. 1978. Molecular structure of elongated forms of electric eel 
acetyl cholinesterase.J. Mol.  Biol.  125:293. 
11.  Rosenberry, T. L., and J. M. Richardson. 1977. Structure of 18S and 14S acetylcholines- 
terase. Identification  of collagen-like subunits that are linked by disulfide bonds to catalytic 
subunits. Biochemistry.  16:3550. 
12.  Mackel, A. M., F. DeLustro, and E. C. LeRoy.  1981. Cell-mediated immunity to homolo- 
gous basement membrane (type IV) collagen in C57BL/6 mice. Clin. Immunol.  Immunopathol. 
21:204. 
13.  Timpl, R., P. Bruckner, and P. P. Fietzek.  1979. Characterization of pepsin fragments of 
basement membrane collagen obtained from a mouse tumor. Eur. J.  Biochem.  95:255. 
14.  Timpl, R., G. R. Martin, P. Bruckner, G. Wick, and H. Wiedemann. 1978. Nature of the 
collagenous protein in a tumor basement membrane. Eur. J. Biochem.  84:43. 
15.  Peterkofsky,  B., and R. Diegelmann. 1971. Use of a mixture of proteinase-free collagenases 
for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry. 
10:988. 
16.  Spiro, R. G.  1964. Periodate oxidation of the glycoprotein fetuin. J. Biol.  Chem. 239:567. 
17.  Ades, E. W., A. Hinson, and J. M. Decker.  1981. Effector  cell sensitivity to sugar moieties. 
I.  Inhibition of human  natural  killer cell  activity by  monosaccharides.  Immunobiology. 
160:248. 
18.  Spiro, R. G. 1967. The structure of the disaccharide unit of the renal glomerular basement 
membrane.J. Biol.  Chem. 242:4813. 
19.  Spiro, R. G.  1966. Analysis of sugars found in glycoproteins. In Methods in Enzymology. 
E. F. Neufeld and V. Ginsburg, editors. Academic Press, Inc., New York.  3-26. ANNE M.  MACKEL, FRANK DeLUSTRO,  AND E.  CARWILE LeROY  1055 
20.  Mackel, A. M., F. DeLustro, F. E. Harper, and E. C. LeRoy. 1982. Antibodies to collagen 
in scleroderma. Arthritis Rheum.  25:522. 
21.  Mackel, A. M.,  F.  DeLustro,  B.,  DeLustro,  H.  H.  Fudenberg, and  E.  C.  LeRoy.  1982. 
Immune response to connective tissue components of the basement  membrane.  Connect. 
Tissue Res.  In press. 
22.  Mackel, A.  M.,  F.  DeLustro,  and  E.  C.  LeRoy.  1982. Immune  response  to  laminin, a 
noncollagenous glycoprotein of basement membrane, in a syngeneic murine system. Proc. 
Soc. Exp.  Biol.  Med.  In press. 
23.  Lee, Y.  C.,  and  R.  Montgomery.  1961. The carbohydrate of ovalbumin. Arch.  Biochem. 
Biophys.  95:263. 
24.  Watson, R.  F., S. Rothbard, and P. Vanamee.  1954.  The antigenicity of rat collagen. J. 
Exp. Med.  99:535. 
25.  Beard, H. K., W. P. Faulk, L. B. Conochie, and L. E. Glynn.  1977. Some immunological 
aspects of collagen. Prog. Allergy.  22:45. 
26.  Michaeli, D.,  and  H.  H.  Fudenberg.  1974. The  incidence and  antigenic specificity of 
antibodies  against  denatured  human  collagen  in  rheumatoid  arthritis.  Clin.  Immunol. 
Immunopathol.  2:153. 
27.  Andriopoulos, N.  A., J.  Mestecky, E. J.  Miller, and  E.  L.  Bradley.  1976. Antibodies to 
native and denatured collagens in the sera of patients with rheumatoid arthritis. Arthritis 
Rheum.  19:613. 
28.  Steffen,  C.,  and  R.  Timpl.  1963. Antigenicity of collagen  and  its  application  in  the 
serological investigation of rheumatoid arthritis. Int. Arch.  Allergy Appl. Immunol.  22:333. 
29.  Stuart, J.  M., A. E.  Postlethwaite, A. S. Townes, and A. H.  Kang.  1980. Cell-mediated 
immunity to collagen and collagen a  chains in rheumatoid arthritis and other rheumatic 
diseases. Amer. J. Med.  69:13. 
30.  Steffen, C.  1969. Tissue antibodies in  rheumatoid  arthritis and  other connective tissue 
diseases. Ann. Immunol.  1:47. 
31.  Stuart, J.  M.,  A.  E.  Postlethwaite, and  A.  H.  Kang.  1976. Evidence for cell-mediated 
immunity to collagen in progressive systemic sclerosis.  J. Lab.  Clin.  Med. 88:601. 
32.  Michaeli,  D.,  and  H.  H.  Fudenberg.  1974. Antibodies  to  collagen  in  patients  with 
emphysema. Clin.  Immunol.  Immunopathol.  3:187. 
33.  Wells, J. V., D. Michaeli, and H. H. Fudenberg.  1973. Antibodies to human collagen in 
subjects with selective IgA deficiency. Clin.  Exp. Immunol.  13:203. 
34.  McAdam, K. P. W. J., H. H. Fudenberg, and D. Michaeli. 1978. Antibodies to collagen in 
patients with leprosy. Clin.  Immunol.  Immunopathol.  9:16. 
35.  Kravis, T. C., A. Ahmed, T. E. Brown, J. D. Fulmer, and R. G. Crystal. 1976. Pathogenic 
mechanisms in pulmonary fibrosis: collagen-induced migration inhibition factor production 
and cytotoxicity mediated by lymphocytes.J. Clin.  Invest.  58:1223. 
36.  Trentham, D. E., R. A. Dynesius, R. E. Rocklin, and J. R. David. 1978. Cellular sensitivity 
to collagen in rheumatoid arthritis. N. Engl. J. Med. 299:327. 
37.  Foidart,J.,J. Foidart, C. Dubois, and P. Mahieu. 1980. Anticorps diriges contre la laminine 
et le procollagen de type IV dans le syndrome de Goodpasture. Nephrologie.  1:57. 
38.  Gay, S., W. Q.  Ward, R.  E.  Gay, and  E. J.  Miller.  1980. Autoantibodies to basement 
membrane collagen: epidermolysis bullosa simplex versus bullous pemphigoid. J.  Cutan. 
Pathol.  7:315. 
39.  Trentham, D. E., A. S. Townes, and A. H. Kang. 1978. Humoral and cellular sensitivity to 
collagen in type II collagen-induced arthritis in rats. J.  Clin.  Invest.  61:89. 
40.  Champion, B. R., and A. R. Poole. 1982. Immunity to homologous type III collagen after 
partial meniscectomy and sham surgery in rabbits. Arthritis Rheum.  25:274. 
41.  Menzel,  E. J., J.  s.  Smolen, and  K.  B.  M.  Reid.  1981. Immunological cross-reactivity 
between the collagen-like fragment of human CIq and human type I collagen. Mol. Immunol. 1056  CROSS-REACTIVITY BETWEEN TYPES !  AND IV  COLLAGEN 
18:765. 
42.  Anglister, L.,  R.  Tarrab-Hazdai,  S.  Fuchs,  and I.  Silman.  1979. Immunological cross- 
reactivity between electric-eel  acetylcholinesterase and  rat-tail  tendon collagen. Eur. J. 
Biochem. 94:25. 
43.  Adelmann, B. C.  1973. The structural basis of ceil-mediated immunological reactions of 
collagen. Recognition by the cutaneous delayed-hypersensitivity  reaction in guinea pigs of 
conformational alterations of rat and calf skin collagen. Immunology. 24:871. 
44.  Butler,  W.  T.,  and  L.  W.  Cunningham.  1965. The  site  of  attachment  of  hexose  to 
tropocollagen.J. Biol.  Chem. 240:3449. 
45.  Butler, W. T., and L. W. Cunningham. 1966. Evidence for the linkage ofa disaccharide to 
hydroxylysine in tropocollagen.J. Biol.  Chem. 241:3882. 
46.  Mahieu, P. M., P. H. Lambert, and G. R. Maghuin-Rogister. 1973. Primary structure of 
a small glycopeptide isolated from human glomerular basement membrane and carrying 
a major antigenic site. Eur. J. Biochem. 40:599. 
47.  Ristelli, J., H. P. Bachinger, J. Engel, H. Furthmayer, and R. Timpl. 1980. 7-S collagen: 
characterization of an unusual basement membrane structure. Eur. J. Biochem. 108:239. 
48.  Kefalides, N. A. 1975. Basement membranes: structural and biosynthetic considerations.J. 
Invest. Dermatol. 65:85. 